IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE
Clinical safety rating: safe
MAOIs can cause hypertensive crisis Can cause insomnia and tachycardia.
Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis and alleviating pain, fever, and inflammation. Pseudoephedrine is a sympathomimetic amine that acts as an alpha-1 adrenergic receptor agonist, causing vasoconstriction in nasal mucosa and reducing congestion.
| Metabolism | Ibuprofen is primarily metabolized in the liver by cytochrome P450 2C9 (CYP2C9) and glucuronidation. Pseudoephedrine is extensively metabolized in the liver by N-demethylation, with CYP450 involvement (CYP2D6) and also undergoes renal excretion. |
| Excretion | Ibuprofen: renal elimination of conjugated metabolites (90%) and unchanged drug (10%); <5% biliary. Pseudoephedrine: renal elimination of unchanged drug (70-90%) and metabolites (10-30%). |
| Half-life | Ibuprofen: 2-4 hours (terminal half-life); pseudoephedrine: 4-6 hours (terminal half-life, prolonged in alkaline urine up to 16 hours). |
| Protein binding | Ibuprofen: 99% bound to albumin; pseudoephedrine: <25% bound to plasma proteins. |
| Volume of Distribution | Ibuprofen: 0.1-0.2 L/kg (low, confined to plasma and extracellular fluid); pseudoephedrine: 2.7-4.5 L/kg (extensive, distributes into total body water). |
| Bioavailability | Ibuprofen: 80-100% (oral); pseudoephedrine: 90-100% (oral). |
| Onset of Action | Ibuprofen: 30-60 minutes (oral) for analgesia; pseudoephedrine: 15-30 minutes (oral) for decongestant effect. |
| Duration of Action | Ibuprofen: 4-6 hours (analgesic effect); pseudoephedrine: 4-6 hours (decongestant effect, sustained-release formulations up to 12 hours). |
| Molecular Weight | 318.39 |
1 tablet (ibuprofen 200 mg/pseudoephedrine HCl 30 mg) orally every 4-6 hours as needed; maximum ibuprofen 1200 mg/day, pseudoephedrine 120 mg/day. Do not exceed 6 tablets in 24 hours.
| Dosage form | TABLET |
| Renal impairment | GFR 30-59 mL/min: reduce dose to 1 tablet every 6-8 hours; maximum 3 tablets/day. GFR 15-29 mL/min: reduce dose to 1 tablet every 8-12 hours; maximum 2 tablets/day. GFR <15 mL/min or dialysis: contraindicated. |
| Liver impairment | Child-Pugh Class A: no adjustment necessary. Child-Pugh Class B: reduce dose to 1 tablet every 6-8 hours; maximum 3 tablets/day. Child-Pugh Class C: contraindicated. |
| Pediatric use | Children ≥12 years: same as adult dosing. Children 6-11 years: not recommended due to pseudoephedrine dose (use individual components adjusted for weight: ibuprofen 5-10 mg/kg/dose every 6-8 hours, pseudoephedrine 1 mg/kg/dose every 6 hours with maximum 60 mg/day). |
| Geriatric use | Initiate at lower end of dosing range (1 tablet every 8 hours) due to increased risk of renal impairment, cardiovascular events, and CNS excitation. Maximum 3 tablets/day. |
| 1st trimester | Avoid. Ibuprofen is contraindicated during first trimester due to risk of miscarriage and congenital malformations; pseudoephedrine is associated with increased risk of gastroschisis. |
| 2nd trimester | Avoid. Ibuprofen is contraindicated due to risk of oligohydramnios and premature closure of ductus arteriosus; pseudoephedrine may cause fetal tachycardia. |
| 3rd trimester | Contraindicated. Ibuprofen causes premature closure of ductus arteriosus and oligohydramnios; pseudoephedrine may cause fetal tachycardia and irritability. |
Clinical note
MAOIs can cause hypertensive crisis Can cause insomnia and tachycardia.
| FDA category | Animal |
| Placental transfer | Both drugs cross the placenta. Ibuprofen: extensive transfer; pseudoephedrine: moderate transfer. |
■ FDA Black Box Warning
Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk. NSAIDs are contraindicated for the treatment of perioperative pain in the setting of coronary artery bypass graft (CABG) surgery.
| Common Effects | Insomnia |
| Serious Effects |
Hypersensitivity to ibuprofen, pseudoephedrine, or any componentHistory of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDsPerioperative pain in setting of coronary artery bypass graft surgeryUncontrolled hypertensionSevere coronary artery diseaseConcurrent use of monoamine oxidase inhibitors (MAOIs) or within 14 days of MAOI useNarrow-angle glaucomaUrinary retentionSevere hepatic impairmentSevere renal impairment (eGFR < 30 mL/min/1.73 m²)Active peptic ulcer disease or gastrointestinal bleedingHistory of cerebrovascular disease or strokePregnancy (especially third trimester)
| Precautions |
Loading safety data…
| Breastfeeding |
| Ibuprofen is present in breast milk in low levels and considered compatible with breastfeeding. Pseudoephedrine is excreted into breast milk and may cause irritability in infants; use with caution, especially in preterm or neonates. The combination product should be avoided if possible. |
| Lactation Rating | L2 (Pseudoephedrine L3) - Ibuprofen is L1 compatible; pseudoephedrine L3 moderately safe. |
| Teratogenic Risk | First trimester: Ibuprofen, as an NSAID, is associated with an increased risk of miscarriage and cardiac defects (relative risk 1.2-1.7). Pseudophedrine is not associated with major malformations. Second trimester: Ibuprofen use is not linked to specific fetal anomalies. Third trimester: Ibuprofen may cause premature closure of the ductus arteriosus, oligohydramnios, and fetal nephrotoxicity; avoid after 30 weeks gestation. Pseudophedrine may cause fetal tachycardia and is associated with gastroschisis if used in early pregnancy. |
| Fetal Monitoring | Maternal: Blood pressure (pseudophedrine may increase BP), renal function, and signs of bleeding (ibuprofen antiplatelet effect). Fetal: Ultrasonography to monitor ductus arteriosus patency and amniotic fluid volume if ibuprofen used in third trimester; fetal heart rate monitoring if pseudophedrine used near term. |
| Fertility Effects | Ibuprofen may reversibly impair fertility in women by inhibiting prostaglandin synthesis, delaying or preventing ovulation. Pseudophedrine has no known direct effect on fertility. |
| Cardiovascular thrombotic events: Increased risk of heart attack and stroke, Gastrointestinal adverse events: Risk of serious GI bleeding, ulceration, and perforation, Cardiovascular effects: Pseudoephedrine can cause increased blood pressure, heart rate, and palpitations, Cerebrovascular events: Pseudoephedrine may increase risk of stroke in patients with hypertension, Renal effects: NSAIDs can impair renal function; use caution in patients with renal impairment, Central nervous system effects: Pseudoephedrine may cause nervousness, dizziness, or sleep disturbances |
| Food/Dietary | Avoid alcohol as it increases risk of gastrointestinal bleeding. High-tyramine foods (aged cheeses, cured meats) may cause hypertensive crisis with pseudoephedrine. Caffeine can potentiate stimulant effects. |
| Clinical Pearls | Ibuprofen/pseudoephedrine is contraindicated in hypertension, coronary artery disease, and concurrent use of MAOIs. Avoid in patients with NSAID-sensitive asthma. Monitor renal function and blood pressure. Use lowest effective dose for shortest duration. Pseudoephedrine can cause CNS stimulation and insomnia. |
| Patient Advice | Do not use if you have high blood pressure, heart disease, or are taking an MAO inhibitor. · Take with food or milk to reduce stomach upset. · Avoid alcohol and other NSAIDs while taking this medication. · Do not take for more than 5 days for cold symptoms or 3 days for fever. · If symptoms persist or worsen, contact your doctor. · Report signs of allergic reaction (rash, difficulty breathing) or gastrointestinal bleeding (black stools, vomiting blood). · May cause dizziness or drowsiness; avoid driving until you know how it affects you. |